Similar articles

• Raloxifene in breast cancer prevention.

  Gennari L, Merlotti D, Paola VD, Nuti R. Gennari L, et al. Expert Opin Drug Saf. 2008 May;7(3):259-70. doi: 10.1517/14740338.7.3.259. Expert Opin Drug Saf. 2008. PMID: 18462184 Review.
• STAR: first-year recruitment efforts set brisk pace for future.

  [No authors listed] [No authors listed] CA Cancer J Clin. 2000 Sep-Oct;50(5):271-2. doi: 10.3322/canjclin.50.5.271. CA Cancer J Clin. 2000. PMID: 11075236 No abstract available.
• Raloxifene vs tamoxifen.

  Goldstein SR. Goldstein SR. JAMA. 2007 Jan 17;297(3):263-4; author reply 264. doi: 10.1001/jama.297.3.263-b. JAMA. 2007. PMID: 17227974 No abstract available.
• [What do we think about selective estrogen receptor modulators?].

  Cortet B. Cortet B. Rev Med Interne. 2001 Dec;22(12):1173-6. doi: 10.1016/s0248-8663(01)00487-8. Rev Med Interne. 2001. PMID: 11794886 French. No abstract available.
• Chemoprevention of breast cancer.

  Zelnak AB, O'Regan RM. Zelnak AB, et al. Curr Probl Cancer. 2004 Jul-Aug;28(4):201-17. doi: 10.1016/j.currproblcancer.2004.05.007. Curr Probl Cancer. 2004. PMID: 15318323 Review. No abstract available.